DK3821912T3 - RPGR-genterapi mod retinitis pigmentosa - Google Patents

RPGR-genterapi mod retinitis pigmentosa Download PDF

Info

Publication number
DK3821912T3
DK3821912T3 DK20199208.8T DK20199208T DK3821912T3 DK 3821912 T3 DK3821912 T3 DK 3821912T3 DK 20199208 T DK20199208 T DK 20199208T DK 3821912 T3 DK3821912 T3 DK 3821912T3
Authority
DK
Denmark
Prior art keywords
gene therapy
retinitis pigmentosa
rpgr gene
rpgr
pigmentosa
Prior art date
Application number
DK20199208.8T
Other languages
Danish (da)
English (en)
Inventor
Michael A Sandberg
Basil Pawlyk
Tiansen Li
Xinhua Shu
Alan Finlay Wright
Robin Ali
Original Assignee
Massachusetts Eye & Ear Infirmary
The Government Of The Us Secretary Department Of Health And Human Services
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye & Ear Infirmary, The Government Of The Us Secretary Department Of Health And Human Services, Ucl Business Ltd filed Critical Massachusetts Eye & Ear Infirmary
Application granted granted Critical
Publication of DK3821912T3 publication Critical patent/DK3821912T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK20199208.8T 2014-07-24 2015-07-17 RPGR-genterapi mod retinitis pigmentosa DK3821912T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028638P 2014-07-24 2014-07-24
EP15825383.1A EP3191139B1 (en) 2014-07-24 2015-07-17 Rpgr gene therapy for retinitis pigmentosa

Publications (1)

Publication Number Publication Date
DK3821912T3 true DK3821912T3 (da) 2024-08-05

Family

ID=55163577

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20199208.8T DK3821912T3 (da) 2014-07-24 2015-07-17 RPGR-genterapi mod retinitis pigmentosa
DK15825383.1T DK3191139T3 (da) 2014-07-24 2015-07-17 RPGR-genterapi til retinitis pigmentosa

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15825383.1T DK3191139T3 (da) 2014-07-24 2015-07-17 RPGR-genterapi til retinitis pigmentosa

Country Status (18)

Country Link
US (2) US10314924B2 (enExample)
EP (2) EP3191139B1 (enExample)
JP (3) JP6654760B2 (enExample)
CN (1) CN107206105A (enExample)
CA (1) CA2991750C (enExample)
CY (1) CY1123793T1 (enExample)
DK (2) DK3821912T3 (enExample)
ES (2) ES2834402T3 (enExample)
FI (1) FI3821912T3 (enExample)
HR (2) HRP20241154T1 (enExample)
HU (2) HUE052781T2 (enExample)
LT (2) LT3191139T (enExample)
PL (2) PL3191139T3 (enExample)
PT (2) PT3191139T (enExample)
RS (2) RS61307B1 (enExample)
SI (2) SI3191139T1 (enExample)
SM (2) SMT202000715T1 (enExample)
WO (1) WO2016014353A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3191139T (pt) * 2014-07-24 2020-11-05 Massachusetts Eye & Ear Infirmary Terapia do gene rpgr para retinite pigmentosa
US20190054117A1 (en) * 2014-12-19 2019-02-21 Novartis Ag Dimerization switches and uses thereof
US10646588B2 (en) 2015-03-11 2020-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RP2 and RPGR vectors for treating X-linked retinitis pigmentosa
GB201516066D0 (en) 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
GB201704192D0 (en) 2017-03-16 2017-05-03 Nightstarx Ltd Treatment of Retinitis Pigmentosa
US11723988B2 (en) 2017-10-20 2023-08-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector
WO2019099696A1 (en) * 2017-11-15 2019-05-23 The Regents Of The University Of Michigan Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
JP2023517929A (ja) 2020-03-11 2023-04-27 マサチューセッツ アイ アンド イヤー インファーマリー Nmnat1関連網膜変性に対する遺伝子療法
CN120350069A (zh) * 2024-01-12 2025-07-22 北京中因科技有限公司 视网膜色素变性动物模型及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
JP3015383B2 (ja) 1987-09-11 2000-03-06 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 形質導入した線維芽およびそれらの使用
DE3851153T2 (de) 1987-12-11 1995-01-05 Hughes Howard Med Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
ATE163046T1 (de) 1990-10-31 1998-02-15 Somatix Therapy Corp Genetische veränderung von endothelzellen
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
AU2044901A (en) 1999-11-24 2001-06-04 Cornell Research Foundation Inc. Inherited retinal diseases at the canine rp3 locus: linkage, marker- and mutation-based tests
GB0008801D0 (en) 2000-04-10 2000-05-31 Medical Res Council Sequences
CN102925445A (zh) * 2011-08-08 2013-02-13 刘军 一种获得rpgr 基因新的转录剪切形式的方法
JP6199965B2 (ja) * 2012-07-11 2017-09-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Rpgrx連鎖性網膜変性のaav媒介型遺伝子治療
GB201412011D0 (en) 2014-07-04 2014-08-20 Ucl Business Plc Treatments
PT3191139T (pt) * 2014-07-24 2020-11-05 Massachusetts Eye & Ear Infirmary Terapia do gene rpgr para retinite pigmentosa

Also Published As

Publication number Publication date
EP3191139A1 (en) 2017-07-19
WO2016014353A1 (en) 2016-01-28
US11045558B2 (en) 2021-06-29
JP2022009333A (ja) 2022-01-14
HRP20241154T1 (hr) 2024-11-22
HUE068183T2 (hu) 2024-12-28
RS61307B1 (sr) 2021-02-26
HRP20202023T1 (hr) 2021-03-05
EP3821912A1 (en) 2021-05-19
HUE052781T2 (hu) 2021-05-28
SMT202400309T1 (it) 2024-11-15
FI3821912T3 (fi) 2024-08-05
PL3821912T3 (pl) 2024-10-28
CA2991750C (en) 2023-02-14
EP3191139B1 (en) 2020-10-07
ES2834402T3 (es) 2021-06-17
PL3191139T3 (pl) 2021-07-05
PT3821912T (pt) 2024-08-01
US20170216454A1 (en) 2017-08-03
SI3191139T1 (sl) 2021-03-31
DK3191139T3 (da) 2020-11-16
CA2991750A1 (en) 2016-01-28
US20200215203A1 (en) 2020-07-09
CN107206105A (zh) 2017-09-26
LT3191139T (lt) 2021-01-25
ES2987090T3 (es) 2024-11-13
CY1123793T1 (el) 2022-05-27
LT3821912T (lt) 2024-09-25
PT3191139T (pt) 2020-11-05
JP2017523239A (ja) 2017-08-17
JP7198329B2 (ja) 2022-12-28
JP2020073536A (ja) 2020-05-14
EP3821912B1 (en) 2024-06-12
US10314924B2 (en) 2019-06-11
SI3821912T1 (sl) 2024-10-30
SMT202000715T1 (it) 2021-01-05
EP3191139A4 (en) 2018-01-10
JP6966532B2 (ja) 2021-11-17
JP6654760B2 (ja) 2020-02-26
RS65909B1 (sr) 2024-10-31

Similar Documents

Publication Publication Date Title
IL284741A (en) Gene therapy for retinitis pigmentosa
ZA201802462B (en) Gene therapy
GB201420139D0 (en) Factor IX gene therapy
DK3821912T3 (da) RPGR-genterapi mod retinitis pigmentosa
PT3177670T (pt) Poli(beta-aminoéster) hiper-ramificado para terapia génica
GB201407322D0 (en) Gene therapy
GB201616821D0 (en) Gene therapy
GB201612104D0 (en) Gene therapy
GB201612105D0 (en) Gene therapy
GB201410595D0 (en) Factor IX gene therapy
SG10201912076UA (en) Gene therapy composition